PBIO - Pressure BioSciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.0800
-0.2000 (-6.10%)
At close: 3:19PM EDT
Stock chart is not supported by your current browser
Previous Close3.2800
Open3.0700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.0000 - 3.0800
52 Week Range1.5200 - 4.1000
Volume3,273
Avg. Volume8,833
Market Cap5.706M
Beta (3Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-15.2450
Earnings DateAug 14, 2019 - Aug 24, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.57
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    Pressure BioSciences' PCT Platform Highlighted at International Conference in China

    SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced that its flagship Barocycler 2320EXTREME instrument was prominently featured at a three-day, internationally-attended scientific conference held at the elite Westlake University (“Westlake”) in Hangzhou, China. One of the primary conference organizers was Professor Tiannan Guo, MD., PhD, a well-known protein research scientist. In 2017, Professor Guo’s Westlake laboratory was named a PBI Center of Excellence.

  • ACCESSWIRE26 days ago

    Pressure BioSciences Enters CBD Market with Launch of Novel Instrument System to Revolutionize Manufacturing of High Quality, Water-Soluble CBD

    SOUTH EASTON, MA / ACCESSWIRE / June 27, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the launch of its BaroShear™ K45 system based on the Company's proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 system is a unique and powerful next generation nanoemulsification system designed to fix one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD oil. Because of these solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to try and improve its solubility in water.

  • ACCESSWIRE27 days ago

    Pressure BioSciences Announces Achievement of First Major Milestone in Development of Potential Breakthrough Processing Method for Higher Quality and Safer Food and Beverages

    Proprietary, Custom Built UST-Based Instrument Delivered to Collaborators at The Ohio State University; OSU Scientists to Study Pressure and Shear Effects on Pathogen Inactivation, Stability, and Quality ...

  • ACCESSWIRElast month

    Pressure BioSciences' Ultra High Pressure HUB Platform Highly Effective in Studies to Develop Improved Methods for Food Safety

    HUB Platform Plays Critical Role in Innovative Research Studies Designed to Increase Understanding of and Develop Methods for the Prevention of Serious Food-Borne Diseases Caused by E. coli and Listeria ...

  • ACCESSWIRElast month

    Pressure BioSciences' PCT Platform Prominently Featured in Record Number of Presentations at Major International Science Conference

    SOUTH EASTON, MA / ACCESSWIRE / June 12, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-base instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that the Company's patented pressure cycling technology ("PCT") platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry ("ASMS"), held from June 1-6, 2019 in Atlanta, GA. The presentations spanned wide ranging applications for PBI's unique PCT platform in scientific studies, particularly their essential use in advancing knowledge and understanding in such areas as cancer research, protein function, molecular biology, and biomarker discovery.

  • ACCESSWIRE2 months ago

    Pressure BioSciences, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

    Q1 Revenue from Newly Created BioPharma and UST Contract Services Significantly Exceeds Services Revenue for All Quarters of 2018 Combined Investor Conference Call Scheduled for Thursday, May 16, 2019 ...

  • ACCESSWIRE2 months ago

    Pressure BioSciences, Inc. to Discuss First Quarter 2019 Financial Results and Provide Business Update

    Conference Call Scheduled for Thursday, May 16 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / May 15, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today ...

  • ACCESSWIRE3 months ago

    Pressure BioSciences Announces CEO Succession Plan

    SOUTH EASTON, MA / ACCESSWIRE / May 1, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, the Founder of the Company, notified the Company's Board of Directors on April 25, 2019 that he plans to step down as President and CEO effective September 9, 2019. Mr. Schumacher has been working with the Company's Board of Directors on leadership succession planning for many months, including the selection of Bradford A. Young, PhD, MBA, as SVP & Chief Commercial Officer ("CCO") for the Company in November 2018.

  • ACCESSWIRE3 months ago

    Pressure BioSciences, Inc. Reports Record Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

    Q4 2018 Total Revenue Increases 37% over Q4 2017, Setting New Record Quarterly High; FY 2018 Total Revenue Increases 10% over FY 2017, Setting New Record Annual High; Initial Revenue Reported from New ...

  • ACCESSWIRE3 months ago

    Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2018 Financial Results and Provide Business Update

    Conference Call Scheduled for Thursday, April 25 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") ...

  • ACCESSWIRE3 months ago

    Uptick Newswire Hosts Dr. Bradford A. Young of Pressure BioSciences, Inc., on The Stock Day Podcast to Discuss the Commercialization of PBI's Proprietary UST and BaroFold Technology Platforms

    PHOENIX, AZ / ACCESSWIRE / April 8, 2019 / Uptick Newswire recently welcomed Dr. Bradford A. Young, Senior Vice President and Chief Commercial Officer of Pressure BioSciences, Inc. (PBIO) ("PBI" or "the Company") to The Stock Day Podcast. The interview was hosted by Mr. Everett Jolly. To begin the interview, Mr. Jolly asked Dr. Young what makes the Company's Ultra Shear Technology (UST) platform one of the most effective methods known when it comes to mixing CBD oil and water.

  • ACCESSWIRE4 months ago

    CBD-Infused Beverages Achieve Quality and Clarity Breakthrough Utilizing Pressure BioSciences' Ultra Shear Technology Platform

    New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption SOUTH EASTON, MA / ACCESSWIRE / April 2, 2019 / Pressure ...

  • Newsfile4 months ago

    Pressure BioSciences Looks to Disrupt the Life Sciences Sector with Its Novel Technologies

    The Company's entry into protein therapeutics and nanoemulsion solutions using breakthrough technologies coupled with its core instruments enable it to provide transformative solutions to the life sciences industry Easton, Pennsylvania--(Newsfile Corp. - March 29, 2019) - Small Caps Daily recently published a full report on Pressure BioSciences, Inc. (OTCQB: PBIO), after the Company's latest surge in press coverage piqued the publication's interest. The media interest is warranted, as it surrounds the commercial launch of ...

  • ACCESSWIRE4 months ago

    Pressure BioSciences Names the Vogel Laboratory at New York University's Center for Genomics and Systems Biology a Center of Excellence

    SOUTH EASTON, MA / ACCESSWIRE / March 27, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced the establishment of a Center of Excellence ("CoE") at Dr. Christine Vogel's laboratory at New York University ("NYU")'s Center for Genomics and Systems Biology (the "GSB Center"). As a Center of Excellence, the Vogel Lab will have free use of the Company's primary instrument system, the Barocycler 2320EXTREME (the "2320EXT") until the end of 2020.

  • ACCESSWIRE5 months ago

    Uptick Newswire Hosts Pressure BioSciences, Inc. on the Stock Day Podcast to Discuss the Company's Recent Breakthrough in Making CBD Oil from Hemp Water Soluble

    PHOENIX, AZ / ACCESSWIRE / March 6, 2019 / Uptick Newswire Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The Company's President and CEO, Mr. Richard T. Schumacher, joined Stock Day host Mr. Everett Jolly to discuss the Company's progress in developing its unique and proprietary Ultra Shear Technology (UST) platform, and the use of this platform to process Hemp CBD Oil into a water-soluble ''nanoemulsion''.

  • ACCESSWIRE5 months ago

    Pressure BioSciences and The Steinbeis Centre Combine Efforts to Develop Revolutionary Method Based on Optimizing Disease-Fighting Antibodies

    SOUTH EASTON, MA / ACCESSWIRE / March 4, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of pressure-based instruments and platform technologies to the life sciences and other industries worldwide, today announced a collaboration with The Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry ("The Steinbeis Centre"), a world-renown German research organization. The collaboration is combining the unique capabilities of PBI's patented pressure cycling technology ("PCT") for sample preparation, protein characterization, and biotherapeutics quality control with the Steinbeis Centre's innovative PROTEX-MS instrument for elucidating structural details of antibody interactions to create an instrument system to accelerate the development of new protein therapeutics and improve existing drug treatments.

  • ACCESSWIRE5 months ago

    Scientific Analyses Confirm Important Benefits from Processing CBD Oil with Pressure BioSciences' Proprietary Ultra Shear Technology Platform

    SOUTH EASTON, MA / ACCESSWIRE / February 21, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries. The Company today announced that analytical testing on hemp-derived CBD oil processed via PBI's Ultra Shear Technology™ (UST™) platform has confirmed that UST processing uniquely achieves the challenging criteria for creating highly-effective "nanoemulsions" of CBD oil in water, without loss or modification of CBD throughout the entire UST process ( 99% recovery).

  • ACCESSWIRE5 months ago

    Pressure BioSciences Makes CBD Oil Water Soluble, Offering Solution to CBD Absorption Issue in Food & Beverages

    New Video Demonstrates PBI's Ultra Shear Technology and Potential Impact in CBD, Nutraceuticals, Foods, Cosmetics, and Other Oil-Based Markets SOUTH EASTON, MA / ACCESSWIRE / February 13, 2019 / Pressure ...

  • GlobeNewswire6 months ago

    Uptick Newswire Hosts Pressure BioSciences, Inc. on the Stock Day Podcast to Discuss Their (1) Just Announced Collaboration With NutraFuels, Inc., (2) the Commercial Launch of Their BioPharmaceuticals Contract Services Business, and (3) the Publication of More Than Twenty Scientific Papers on the Company’s Unique Pressure-Based Products During 2018

    Uptick Newswire Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, to update Stock Day’s listeners on PBI’s three recent press releases. The Company’s President and CEO, Mr. Richard T. Schumacher, joined Stock Day’s Mr. Everett Jolly to discuss their recent successes. Mr. Jolly began the interview by asking Mr. Schumacher to explain to new listeners the Company’s products and how the Company generates revenue.

  • ACCESSWIRE6 months ago

    Pressure BioSciences, Inc and NutraFuels, Inc to Collaborate on the Development of Water-Soluble Nanoemulsion-based Nutraceuticals

    Primary Goal is to Optimize PBI's UST Platform for the Development and Manufacture of the Next Generation of New and Improved Nutraceutical and Other Large Market Emulsion-based Products, Such as Cosmetics and Pharmaceuticals. SOUTH EASTON, MA / ACCESSWIRE / January 30, 2019 / Pressure BioSciences, Inc. (PBIO) and NutraFuels, Inc. (NTFU) (together, the ''Companies'') today announced a collaboration to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform.

  • Newsfile6 months ago

    NutraFuels, Inc. and Pressure BioSciences, Inc. to Collaborate on the Development of Water-Soluble Nanoemulsion-based Nutraceuticals

    Coconut Creek, Florida--(Newsfile Corp. - January 30, 2019) - NutraFuels, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the "Companies") today announced a collaboration to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which ...

  • ACCESSWIRE6 months ago

    Record Number of Scientific Papers Citing the Significant Benefits of Pressure BioSciences' PCT Platform Published in 2018

    SOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that more than 20 scientific papers citing the advantages of the Company's pressure cycling technology ("PCT") platform were published by independent researchers worldwide in 2018. The publications, authored by scientists from academia, government, and industry, described a wide range of enabling applications for PBI's patented PCT Platform in cancer research, biomarker discovery, and food safety, as well as in proteomic and molecular biology studies.

  • ACCESSWIRE6 months ago

    Pressure BioSciences, Inc. Announces Commercial Launch of its Unique Biopharmaceuticals Contract Services Business

    SOUTH EASTON, MA / ACCESSWIRE / January 7, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of enabling high pressure-based instruments, consumables, and related services for the worldwide life sciences industry, today announced the commercial launch of its Biopharmaceuticals Contract Services Business. The launch of this new business has been eagerly anticipated following the Company's acquisition of the assets of BaroFold, Inc. in December 2017, including patents, equipment, and other intellectual property relating to Barofold's unique, high pressure-based protein disaggregation and refolding platform. PBI expects that the unique Barofold technology platform will substantially improve the quality and costs of manufacturing protein therapeutics, by helping to resolve protein aggregation, improving solubility, and refolding complex misfolded protein therapeutic molecules into their desired, therapeutically-optimized conformations for improved drug efficacy and lower immunogenicity.

  • ACCESSWIRE7 months ago

    Major Cancer Research Center Reports Pressure BioSciences' PCT Platform Could Play Major Role in Improving Cancer Diagnosis and Treatment

    SOUTH EASTON, MA / ACCESSWIRE / December 18, 2018 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries. The Company today announced that a team of scientists from the Centre for the Proteome of Human Cancer ("ProCan”) has published a recommended, streamlined, proteomic sample preparation protocol built around PBI's Barocycler instrument system, designed to help optimize the identification and use of novel cancer biomarkers for the improved diagnosis and treatment of cancers.